Cool. I love this board. I get info even before my google alerts.
I also found this interesting:
"In Phase 4 development, the Company plans to conduct additional trials to expand the profile of MIN-101. These may potentially include a study comparing the rate of psychosis relapses in patients treated with MIN-101, standard of care with antipsychotics or placebo. In addition, the Company may conduct a trial in adolescents at high risk for schizophrenia who during the prodromal phase manifest negative symptoms. "
So it seems there may be some risk of relapse without an antipsychotic. But of course we'll have to wait and see. They're not testing this as an add on therapy, but if there is a high level of relapse it might have to be used as one. Another concern would be how much negative symptoms are impacted by participants going off their antipsychotics in order to participate in the study. If a large effect comes from that, it could make it difficult to tell the effects of MIN 101 vs a "med holiday".
I'm excited about the prodrome study though because there are a limited number of studies on the prodrome.